H. Moses Murdock
@haematognomist
Heme/Onc Fellow @DanaFarber @MGHCancerCenter | IM Residency: @BrighamMedRes | MD @PennMedicine | Interests: Leukemia, BMT, MRD 🩸 🧬 | Pura Vida! 🇺🇸🇨🇷🇯🇲
ID:1083006840332537857
https://connects.catalyst.harvard.edu/Profiles/display/Person/193047 09-01-2019 14:25:26
2,0K تغريدات
4,5K متابعون
3,2K التالية
Thanks Anand Patel! Was a fun and educational experience putting this together with mentors Dr. Garcia and Dr. Ho 🩸
The impact of molecular ontogeny in AML treated with HMA+VEN is unknown. We found that Secondary ontogeny is selectively responsive to VEN added to HMA and the addition of VEN has no clinical benefit in TP53-mutated AML. rdcu.be/dCCZI Leukemia Journal #amlsm Dana-Farber News
Update: Cigna Healthcare after a peer to peer review Cigna Healthcare denied my request. It was denied by a family medicine practitioner who has never in their life treated a patient with leukemia. In what world are we living here? Cigna Healthcare is this how you treat your patients? Really? Do better!!
Diagnosis and classification of myelodysplastic syndromes
loom.ly/pqtwDkM #myeloidneoplasia #reviewarticles #reviewseries
Congrats to the next wave of Dana-Farber / Mass General Cancer Center fellows!! An incredible group coming from MGH IM Residents! Matt Meizlish Dylan Martini Ben Ouyang 👨🔬👨⚕️ Sienna Durbin
The Brigham and Women's Hospital and Dana-Farber have had a wonderful, collaborative working relationship for 3 decades.
Here's how most of us who work here felt when we heard it was ending.
Really, really sad -- for both us and (especially) for our patients. nejm.org/doi/full/10.10…
🎯 Reduced intensity #HematopoieticCellTransplantation improves overall survival in MDS patients w/ TP53 mutations irrespective of TP53 allelic status #MyelodysplasticSyndrome ➡️ brnw.ch/21wDbev #mpnsm #HCT Coleman Lindsley
Excited to share our paper in Journal of Clinical Oncology: allogeneic HCT should be considered as a curative treatment for all patients with high-risk MDS, even for those with TP53 mutations.
Thanks to all collaborators Coleman Lindsley Corey Cutler Chris Hourigan BMT CTN
ascopubs.org/doi/10.1200/JC…
A new study in Journal of Clinical Oncology by Coleman Lindsley & Dana-Farber researchers suggests that allogenic hematopoietic cell transplant should be considered as a viable option for all patients with high-risk MDS, even those with TP53 mutations.
Research Summary ➡️ ms.spr.ly/60119ujKP
Is the effect of obesity on toxicities and Survival in AYAs with ALL differ by age? who influence most - age or BMI? Would like to thank my amazing mentor Marlise R. Luskin MD, MSCE and collaborators for a wonderful opportunity to try and answer these questions.
💩@jeanpadillamd sharing why you should consider Brigham and Women's GI for training!
🌆Mass General Brigham & Harvard University community
🥼Provision of skills & time to grow as a clinician & investigator
👥Faculty🟰Kind, supportive, collaborative
ACG
American Gastroenterological Association (AGA)
ABGH
Dr. AC Gomez AC Gomez sharing why to chose Brigham Yen renal for fellowship training!
🥼 #MedPeds & tailored training plan
👥Faculty🟰 #mentors , colleagues & friends
🩺Diverse patient pathology
🏥Access to network of resources Mass General Brigham & Harvard University
BWH Nephrology